Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| bioAffinity Technologies, Inc.BIAF · Entity 8368 | Director | July 01, 2024 | July 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
bioAffinity Technologies, Inc.
Report date July 01, 2024 · Filed July 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 54,748 |
Reported balance
After 2024-07-01 transaction · row 1
1 source rowRow 1 · 2024-07-01 · Grant · Acquired 33,784 · Balance 54,748 F1: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2024 Filed Jul 2, 2024 18:47 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 33,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-026086 · ownership.xml · nonDerivative · entry 1 Platt Jamie · CIK 0002003040 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,748 F1 · shares: Grant of restricted shares of common stock, par value $0.007 per share, that vest pro rata on a monthly basis for 12 months commencing on August 1, 2024. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:45 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 8,296 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-023997 · ownership.xml · nonDerivative · entry 1 Platt Jamie · CIK 0002003040 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,964 F1 · shares: Grant of restricted shares of common stock, par value $0.007 per share, that vest immediately. Read SEC document |
| January 01, 2024 Filed Jan 24, 2024 20:52 UTC | bioAffinity Technologies, Inc. BIAF · Entity 8368 | GrantCommon Stock | 12,668 | $1.48 | $18,748.64 |
DisclosureSEC source: 0001493152-24-003694 · ownership.xml · nonDerivative · entry 1 Platt Jamie · CIK 0002003040 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,668 F1 · shares: Represents a grant from the Issuer to Ms. Platt of 12,668 restricted shares of Common Stock, on January 1, 2024 under the Issuer's 2014 Equity Incentive Plan, which shares of restricted stock will vest ratably over three months of continued service beginning on the date of grant and which represents a restricted stock award valued at $18,750 granted by the Issuer to each of its directors each quarter during the calendar year. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.